Oculis Holding AG will participate in the H.C. Wainwright Ophthalmology Virtual Conference on August 13, 2025.
Quiver AI Summary
Oculis Holding AG, a biopharmaceutical company based in Zug, Switzerland, announced its participation in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. During the event, Chief Financial Officer Sylvia Cheung will present a corporate update, available for replay via webcast at 7:00 am ET, while President of R&D Snehal Shah will engage in a live panel discussion on pivotal-stage assets for retinal disorders from 11:00 am to 12:00 pm ET, also available for replay. Oculis is focused on addressing unmet medical needs in ophthalmic and neuro-ophthalmic conditions and is advancing innovative treatments, including a potential non-invasive eye drop for diabetic macular edema and other therapeutics in late-stage clinical trials.
Potential Positives
- Oculis will be presenting a corporate update at a prominent industry conference, which may enhance visibility and attract investor interest.
- Management participation in discussions about pivotal-stage assets demonstrates Oculis' commitment to addressing unmet medical needs in the ophthalmic and neuro-ophthalmic markets.
- The company highlights a highly differentiated late-stage clinical pipeline, including innovative treatments that could position Oculis as a leader in its field.
- Expertise of the management team and backing from leading international healthcare investors indicates strong support for the company's growth and innovation strategies.
Potential Negatives
- Non-specificity regarding the outcomes or data related to ongoing clinical trials may raise concerns about the company's transparency and the effectiveness of its product pipeline.
- Participation in the conference may imply that the company is seeking to bolster investor confidence, which could suggest underlying weaknesses in current investor sentiment or market performance.
- The emphasis on multiple late-stage candidates without concrete datelines or expected results could lead to skepticism regarding the company’s ability to deliver successful outcomes in a competitive biopharmaceutical market.
FAQ
What is Oculis Holding AG?
Oculis Holding AG is a global biopharmaceutical company focusing on innovations for ophthalmic and neuro-ophthalmic conditions.
When will Oculis participate in the H.C Wainwright Conference?
Oculis will participate in the conference on August 13, 2025.
Who will present at the Oculis conference session?
Sylvia Cheung, CFO, will present a corporate update, and Snehal Shah, President of R&D, will join a live panel discussion.
Where can I access the Oculis conference presentations?
Presentations will be available via webcast on Oculis’ Events & Presentation page under the Investors & Media section.
What are Oculis' key product candidates?
Oculis' key candidates include OCS-01, OCS-05, and OCS-02, targeting diabetic macular edema and neuro-ophthalmic diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCS Hedge Fund Activity
We have seen 16 institutional investors add shares of $OCS stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC added 563,078 shares (+32.4%) to their portfolio in Q1 2025, for an estimated $10,715,374
- SR ONE CAPITAL MANAGEMENT, LP added 322,500 shares (+inf%) to their portfolio in Q1 2025, for an estimated $6,137,175
- ALYESKA INVESTMENT GROUP, L.P. added 131,332 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,499,247
- ACUTA CAPITAL PARTNERS, LLC added 125,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,378,750
- NAN FUNG GROUP HOLDINGS LTD added 78,324 shares (+17.9%) to their portfolio in Q1 2025, for an estimated $1,490,505
- CITADEL ADVISORS LLC removed 22,911 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $435,996
- XTX TOPCO LTD removed 13,249 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $252,128
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OCS Analyst Ratings
Wall Street analysts have issued reports on $OCS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 05/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/17/2025
- Baird issued a "Outperform" rating on 03/13/2025
To track analyst ratings and price targets for $OCS, check out Quiver Quantitative's $OCS forecast page.
$OCS Price Targets
Multiple analysts have issued price targets for $OCS recently. We have seen 3 analysts offer price targets for $OCS in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $33.0 on 05/09/2025
- Yi Chen from HC Wainwright & Co. set a target price of $32.0 on 04/17/2025
- Colleen Kusy from Baird set a target price of $41.0 on 03/13/2025
Full Release
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C Wainwright 5 th Annual Ophthalmology Virtual Conference on August 13, 2025.
- Sylvia Cheung, Oculis’ Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ET
- Snehal Shah, Oculis’ President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets for Retinal Disorders. The panel discussion will also be made available via webcast for replay.
Links to access the corporate update presentation and the panel discussion will be posted to Oculis’ website on the Events & Presentation page under the Investors & Media section.
- ENDS -
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
[email protected]
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]
